Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869815 | 0.81 | DRD1 (0.38) | GAATSHR | |
| SCHEMBL486086 | 0.80 | GAA (0.34) | GAATSHR | |
| SCHEMBL13189635 | 0.76 | HTR2A (0.33) | — | |
| SCHEMBL1189193 | 0.72 | IDH1 (0.31) | — | |
| SCHEMBL486490 | 0.72 | IDH1 (0.31) | — | |
| SCHEMBL12869811 | 0.70 | DRD1 (0.40) | GAATSHR | |
| SCHEMBL486183 | 0.70 | SCN9A (0.44) | GAA | |
| SCHEMBL486193 | 0.69 | GAA (0.34) | GAATSHR | |
| SCHEMBL19205693 | 0.67 | MAPK14 (0.39) | GAATSHR | |
| SCHEMBL12869813 | 0.67 | DRD1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411388-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| WO-2010111418-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034691-A1 | Process for the Production of Fused, Tricyclic Sulfonamides | CBR3, DRD4, SBDS | GAA 1643/4885TSHR 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.